NCT03223610 2026-03-12Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaNational Institutes of Health Clinical Center (CC)Phase 1/2 Recruiting155 enrolled